Christopher Espana, MD
Family Medicine · Saint Louis, MONPI 1003922634
Payments from drug & device makers
Across 382 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$680
- Novo Nordisk$665
- GSK$595
- Pfizer$533
- Lilly USA, LLC$443
- plus $4K from 31 others
What the payments were for
- Travel & lodging$20%
- Food & beverage$8,52796%
- Education$3514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 95 | $2,368 |
| AstraZeneca | 30 | $680 |
| Novo Nordisk | 38 | $665 |
| GSK | 27 | $595 |
| Pfizer | 38 | $533 |
| Lilly USA, LLC | 21 | $443 |
| Astellas Pharma US Inc | 9 | $440 |
| Sanofi | 4 | $417 |
| Amgen | 24 | $365 |
| Johnson & Johnson | 7 | $299 |
| Regeneron Healthcare Solutions, Inc. | 2 | $220 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $159 |
| Biohaven Pharmaceuticals, Inc. | 3 | $152 |
| Sanofi-aventis U.S. LLC | 8 | $133 |
| Smith+Nephew | 2 | $122 |
| Otsuka America Pharmaceutical, Inc. | 6 | $121 |
| Genentech USA, Inc. | 1 | $112 |
| Boehringer Ingelheim | 5 | $104 |
| Bayer | 6 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $86 |
| Merck | 6 | $84 |
| E.r. Squibb & Sons, L.L.C. | 5 | $84 |
| Amarin Pharma, Inc. | 5 | $84 |
| Abbott | 4 | $80 |
| Convatec Inc. | 1 | $79 |
| Exact Sciences | 3 | $66 |
| Phathom Pharmaceuticals, Inc. | 2 | $64 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Novartis | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Dexcom, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$439
- XARELTO$210
- LINZESS$125
- AIRSUPRA$125
- Ozempic$124
- NUCALA$123
- Santyl$121
- PICO 7 Single Use Negative Pressure Wound Therapy$121
- Allevyn Life$121
- Durafiber$121
- Acticoat Range$121
- NURTEC ODT$115
- XOLAIR$112
- VRAYLAR$108
- TEZSPIRE$103
How this compares
$8,881 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 151 | $139,611 |
| OzempicSemaglutide | 85 | $108,619 |
| TrulicityDulaglutide | 38 | $43,073 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $42,565 |
| TradjentaLinagliptin | 23 | $35,063 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $31,719 |
| JardianceEmpagliflozin | 26 | $29,282 |
| XareltoRivaroxaban | 24 | $25,737 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 30 | $22,522 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $16,539 |
| JanuviaSitagliptin Phosphate | 21 | $16,359 |
| Semglee (Yfgn)Insulin Glargine-Yfgn | 17 | $14,119 |
| MounjaroTirzepatide | 11 | $11,574 |
| Levothyroxine Sodium | 473 | $11,257 |
| MyrbetriqMirabegron | 21 | $8,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $533 | $143,777200 claims |
| Novo NordiskOzempic | $665 | $108,61985 claims |
| Boehringer IngelheimTradjenta, Jardiance | $104 | $64,34549 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy | $595 | $61,323104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $443 | $54,64749 claims |
| Johnson & JohnsonXarelto | $299 | $25,73724 claims |
| MerckJanuvia | $84 | $16,35921 claims |
| Astellas Pharma US IncMyrbetriq | $440 | $8,04821 claims |
| AbbVieSynthroid | $2,368 | $2,30729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Saint Louis
- Rupal TrivediSaint Louis$10.6M
- Emily DoucetteSaint Louis$155K
- Michael DonovanSaint Louis$78K
- Jarad SchwartzSaint Louis$36K
- Christina RobinsSaint Louis$27K
- Michael SpeziaSaint Louis$26K
- Amanda BooneSaint Louis$17K
- David GlickSaint Louis$17K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.